Related Experiment Video
Updated: Jul 20, 2025
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
Doxorubicin-induced transcriptome meets interactome: identification of new drug targets
1Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, İstanbul Bilgi University, İstanbul, Turkey.
Abstract:
The working mechanism of the chemotherapeutic drug doxorubicin, which is frequently used in cancer treatment, its effects on cell metabolism, and pathways activated solely by doxorubicin are not fully known. Understanding these principles is important both in improving existing therapies and in finding new drug targets. Here, I describe a systems-biology approach to find a generalizable working principle for doxorubicin by superimposition of human interactome over gene datasets commonly expressed among various cancer types. The common -in at least two different diseases-transcriptional response of distinctive cancer cell lines to doxorubicin was reflected via 199 significantly and differentially expressed genes, mostly related to the regulation of transcription. Then, by integrating with interactome data, an active network was constructed allowing detection of clusters. Since each cluster defines densely connected regions, another level of understanding of functional principles is provided. Significant clusters were associated with the linked transcription factors and transcriptional factor enrichment analysis within these regulatory networks led to the proposition of Pou5f1b, Znf428, Prmt3, Znf12, Erg, Tfdp1, Foxm1, and Cenpa as new drug targets in drug development that can be applied in different cancer types.
Insights
This study uses systems biology to uncover doxorubicin's cancer-fighting mechanism. Researchers identified key gene networks and potential new drug targets for improved cancer therapies.
Area of Science:
- Oncology
- Systems Biology
- Pharmacology
Background:
- The precise working mechanism of doxorubicin, a common chemotherapy drug, remains incompletely understood.
- Its effects on cancer cell metabolism and specific activated pathways require further elucidation for therapy improvement and new target identification.
Purpose of the Study:
- To elucidate the generalizable working principle of doxorubicin using a systems biology approach.
- To identify novel drug targets for diverse cancer types by analyzing gene expression and protein-protein interaction networks.
Main Methods:
- Superimposition of the human interactome onto gene datasets commonly expressed across various cancer types.
- Analysis of differentially expressed genes in response to doxorubicin across distinct cancer cell lines.
- Construction and analysis of active biological networks and significant clusters.
Main Results:
- Identified 199 significantly and differentially expressed genes, primarily involved in transcriptional regulation, common to at least two cancer types treated with doxorubicin.
- Constructed an active network revealing densely connected functional clusters.
- Transcriptional factor enrichment analysis identified Pou5f1b, Znf428, Prmt3, Znf12, Erg, Tfdp1, Foxm1, and Cenpa as potential drug targets.
Conclusions:
- The study provides a deeper understanding of doxorubicin's functional principles in cancer treatment.
- Proposed novel drug targets that hold potential for application in developing new therapies for multiple cancer types.
Related Concept Videos
01:26Drug Discovery: Overview
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...